To further interrogate the translational potential of MET and RET expression and cabozantinib treatment in SCNPC, we evaluated two adenocarcinoma LuCaP CRPC PDX models (LuCaP 86.2CR and LuCaP 147CR), 4 SCNPC PDX models (LuCaP 49, 93, 145.1 and 173.1) and the SCNPC NCI-H660 cell line. The gene discussed is RET; the disease is adenocarcinoma.